1
|
Class of antiretroviral drugs and the risk of myocardial infarction.
|
N Engl J Med
|
2007
|
12.93
|
2
|
Combination antiretroviral therapy and the risk of myocardial infarction.
|
N Engl J Med
|
2003
|
12.23
|
3
|
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
|
Arch Intern Med
|
2006
|
9.21
|
4
|
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
|
Lancet
|
2008
|
8.73
|
5
|
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
|
AIDS
|
2003
|
5.61
|
6
|
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.
|
Clin Infect Dis
|
2005
|
5.20
|
7
|
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
|
AIDS
|
2005
|
4.40
|
8
|
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.
|
AIDS
|
2010
|
3.47
|
9
|
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
|
J Infect Dis
|
2010
|
3.30
|
10
|
Changing incidence of central nervous system diseases in the EuroSIDA cohort.
|
Ann Neurol
|
2004
|
3.06
|
11
|
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
|
J Infect Dis
|
2013
|
3.04
|
12
|
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.
|
J Infect Dis
|
2002
|
2.87
|
13
|
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
|
AIDS
|
2010
|
2.85
|
14
|
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
|
Int J Epidemiol
|
2011
|
2.80
|
15
|
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
|
J Infect Dis
|
2005
|
2.73
|
16
|
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.
|
Eur J Cardiovasc Prev Rehabil
|
2010
|
2.70
|
17
|
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.
|
J Acquir Immune Defic Syndr
|
2010
|
2.59
|
18
|
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
|
PLoS Med
|
2013
|
2.49
|
19
|
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
|
AIDS
|
2008
|
2.27
|
20
|
Chronic renal failure among HIV-1-infected patients.
|
AIDS
|
2007
|
2.07
|
21
|
Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).
|
Circulation
|
2009
|
2.01
|
22
|
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina.
|
AIDS
|
2009
|
1.81
|
23
|
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.
|
Int J Epidemiol
|
2002
|
1.79
|
24
|
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.
|
AIDS
|
2011
|
1.68
|
25
|
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.
|
Epidemiology
|
2011
|
1.59
|
26
|
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
|
Clin Infect Dis
|
2010
|
1.54
|
27
|
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
|
PLoS Med
|
2012
|
1.54
|
28
|
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies.
|
Cancer
|
2010
|
1.53
|
29
|
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
|
AIDS
|
2005
|
1.52
|
30
|
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited.
|
J Acquir Immune Defic Syndr
|
2003
|
1.44
|
31
|
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
|
Antivir Ther
|
2003
|
1.42
|
32
|
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
|
Cancer
|
2004
|
1.39
|
33
|
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
|
Euro Surveill
|
2015
|
1.29
|
34
|
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe.
|
J Acquir Immune Defic Syndr
|
2006
|
1.27
|
35
|
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
|
AIDS
|
2008
|
1.25
|
36
|
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.
|
Clin Infect Dis
|
2014
|
1.25
|
37
|
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.
|
AIDS
|
2012
|
1.16
|
38
|
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
|
AIDS
|
2007
|
1.15
|
39
|
Predictors of hypertension and changes of blood pressure in HIV-infected patients.
|
Antivir Ther
|
2005
|
1.14
|
40
|
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
|
AIDS
|
2008
|
1.11
|
41
|
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
|
Int J Epidemiol
|
2012
|
1.11
|
42
|
Changes in viral load in people with virological failure who remain on the same HAART regimen.
|
Antivir Ther
|
2003
|
1.04
|
43
|
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
|
AIDS
|
2014
|
1.03
|
44
|
The naive CD4+ count in HIV-1-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recovery.
|
Scand J Infect Dis
|
2002
|
1.00
|
45
|
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.
|
Antivir Ther
|
2010
|
1.00
|
46
|
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
|
AIDS
|
2008
|
0.99
|
47
|
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
|
AIDS
|
2013
|
0.98
|
48
|
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.
|
BMC Infect Dis
|
2013
|
0.98
|
49
|
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.
|
HIV Clin Trials
|
2011
|
0.98
|
50
|
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
|
AIDS
|
2004
|
0.96
|
51
|
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
|
AIDS
|
2003
|
0.95
|
52
|
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study.
|
PLoS One
|
2012
|
0.95
|
53
|
Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial.
|
J Clin Epidemiol
|
2007
|
0.94
|
54
|
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
|
Scand J Infect Dis
|
2012
|
0.93
|
55
|
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
|
J Infect Dis
|
2002
|
0.93
|
56
|
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.
|
AIDS
|
2011
|
0.91
|
57
|
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
|
J Hepatol
|
2013
|
0.90
|
58
|
Elevated triglycerides and risk of myocardial infarction in HIV-positive persons.
|
AIDS
|
2011
|
0.89
|
59
|
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
|
Antivir Ther
|
2004
|
0.89
|
60
|
TTV viral load as a marker for immune reconstitution after initiation of HAART in HIV-infected patients.
|
HIV Clin Trials
|
2002
|
0.88
|
61
|
Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord.
|
AIDS
|
2014
|
0.87
|
62
|
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.
|
AIDS
|
2015
|
0.87
|
63
|
Deteriorating renal function and clinical outcomes in HIV-positive persons.
|
AIDS
|
2014
|
0.86
|
64
|
Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.86
|
65
|
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.
|
AIDS
|
2015
|
0.85
|
66
|
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.
|
J Acquir Immune Defic Syndr
|
2015
|
0.85
|
67
|
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
|
AIDS
|
2012
|
0.85
|
68
|
The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results.
|
Cent Eur J Public Health
|
2008
|
0.84
|
69
|
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C.
|
Scand J Infect Dis
|
2006
|
0.84
|
70
|
Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe.
|
Eur Respir J
|
2013
|
0.83
|
71
|
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
|
Antivir Ther
|
2005
|
0.82
|
72
|
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study.
|
BMC Infect Dis
|
2012
|
0.82
|
73
|
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
|
Antivir Ther
|
2012
|
0.81
|
74
|
Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.
|
AIDS
|
2014
|
0.80
|
75
|
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study.
|
J Acquir Immune Defic Syndr
|
2013
|
0.79
|
76
|
HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective.
|
BMC Infect Dis
|
2014
|
0.79
|
77
|
Dialysis and renal transplantation in HIV-infected patients: a European survey.
|
J Acquir Immune Defic Syndr
|
2010
|
0.79
|
78
|
Incidence of abacavir hypersensitivity reactions in euroSIDA.
|
Antivir Ther
|
2008
|
0.78
|
79
|
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.
|
BMC Nephrol
|
2014
|
0.77
|
80
|
Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
|
Scand J Infect Dis
|
2008
|
0.77
|
81
|
The cardiovascular risk management for people living with HIV in Europe: how well are we doing?
|
AIDS
|
2016
|
0.77
|
82
|
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
|
AIDS
|
2004
|
0.76
|
83
|
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?
|
AIDS
|
2016
|
0.75
|
84
|
Associations between HIV-RNA-based indicators and virological and clinical outcomes.
|
AIDS
|
2016
|
0.75
|
85
|
Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
86
|
Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.
|
AIDS
|
2017
|
0.75
|
87
|
Let us put biotechnology on the global agenda.
|
N Biotechnol
|
2009
|
0.75
|